Corticospinal motor neurons (CSMN) are the cortical component of motor neuron circuitry, which controls voluntary movement and degenerates in diseases such as amyotrophic lateral sclerosis, primary lateral sclerosis and hereditary spastic paraplegia. By using dual labeling combined with molecular marker analysis, we identified AAV2-2 mediated retrograde transduction as an effective approach to selectively target CSMN without affecting other neuron populations both in wild-type and hSOD1
Introduction
In amyotrophic lateral sclerosis (ALS), unlike other motor neuron diseases, both the cortical and spinal components of motor neuron circuitry progressively degenerate (Brown and Robberecht, 2001; Ravits et al., 2007) . Therefore, bringing effective treatments to ALS requires targeting both the spinal motor neurons (SMN) in the spinal cord and the corticospinal motor neurons (CSMN) in the motor cortex. CSMN degeneration results in lack of cortical input and impairs voluntary movement in other motor neuron disorders, such as primary lateral sclerosis and hereditary spastic paraplegia (Fink, 2002 (Fink, , 2006 Rainier et al., 2003) . Therefore, due to the central involvement of CSMN in motor neuron circuitry and their selective vulnerability and degeneration in various diseases, it is imperative to understand cellular mechanisms for CSMN vulnerability and to develop CSMN directed gene delivery approaches in the cerebral cortex.
Viral vectors offer a great tool for gene therapy and replacement studies in CNS (Kootstra and Verma, 2003; Verma and Weitzman, 2005) . Recombinant, adeno-associated viruses (AAV) are ideal candidates for retrograde transduction of projection neurons and are extensively used to target SMN. AAV2-IGF-1 injected into the muscle of hSOD1 G93A ALS transgenic mice, one of the bestcharacterized mouse models of ALS (Gurney et al., 1994) , retrogradely transduced SMN and increased life span (Kaspar et al., 2003) . Intravascular administration of AAV9 (Foust et al., 2009 ) and intrathecal injections of AAV6 and AAV9 at the level of the lumbar spinal cord transduced SMN throughout the spinal cord (Snyder et al., 2011) . Intramuscular delivery of AAV6 encoding silencer shSOD1 RNA transduced SMN, but failed to alter disease course in the hSOD1 G93A mouse (Towne et al., 2011) . Moreover, CST fibers were labeled and mixed neuron populations were transduced by direct AAV injection into the motor cortex (Hutson et al., 2011) , but effective retrograde transduction of CSMN has never been achieved, even though AAVmediated gene therapy approaches have been considered for ALS (Nizzardo et al., 2011) .
In an effort to build gene delivery approaches selectively targeting CSMN and to reveal cytoarchitectural changes that correlate with cellular mechanisms underlying CSMN vulnerability, we used an AAVmediated retrograde transduction strategy coupled with cellular analysis. We investigated whether a distinct set of AAV serotypes can be used to retrogradely transduce CSMN following precise injection into the corticospinal tract (CST), without affecting other spinal cord neurons and circuitries. AAV2-2 was found to be most effective in CSMN gene delivery in both wild-type (WT) and hSOD1
G93A
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